🔎 Trials Near Me

Home › Cancer (all types) › NCT06207032

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

RecruitingObservational study

Who can join

Ages 18 to 99 · All sexes

Full eligibility criteria
Inclusion Criteria:

1. ≥18 years of age
2. Willing to participate in the research
3. Able to provide informed consent
4. Must be diagnosed with cancer

Exclusion Criteria:

1\. Not willing or able to have additional blood samples collected

About the study

This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.

Sponsor: Tempus AI · Participants: 500 · Started: Jun 26, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06207032

Locations in the U.S.

AlabamaAlabama Oncology, Birmingham
CaliforniaPIH Health Whittier Hospital & PIH Health Physicians, Whittier
ConnecticutEastern CT and Hematology and Oncology Associates, Norwich
FloridaCancer Specialists of North Florida, Jacksonville
GeorgiaMorehouse, Atlanta
Piedmont Healthcare, Atlanta
IllinoisSouthern Illinois Healthcare, Carterville
Hope and Healing Cancer Services, Hinsdale
Cancer Care Specialists of Illinois, O'Fallon
Illinois Cancer Care, Peoria
IndianaGoshen Center for Cancer Care, Goshen
MarylandFrederick Health Regional System, Frederick
MassachusettsSouthcoast Centers for Cancer Care, Fairhaven
MissouriHannibal Regional Healthcare System, Inc., Hannibal
Lake Regional Health, Osage Beach
Oncology Hematology Associates, Springfield
NevadaCancer Care Specialists - Reno, Reno
New YorkHematology Oncology Associates of Central NY, East Syracuse
Cayuga Medical Center, Ithaca
North DakotaSanford Roger Maris Cancer Center (Fargo), Fargo
OhioAultman Medical Group, Canton
Taylor Cancer Research Center, Maumee
PennsylvaniaCancer Care Associates of York, York
WashingtonCancer Care Northwest, Spokane

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.